Tag:
Xarelto
Latest Headlines
Latest Headlines
UPDATED: Bayer, J&J test Xarelto uses, even as ACS indication eludes
Johnson & Johnson and Bayer AG are looking on the bright side of things when it comes to Xarelto. They are undertaking new trials they hope will lead to much wider use of the new kind of blood thinner. The announcement comes days after the FDA for the second time rebuffed their bid to get it a coveted approval for treatment of acute coronary syndrome (ACS).
Bayer, J&J's Xarelto again falls short in bid for ACS use
Johnson & Johnson and Bayer tried again to persuade FDA on a new use for Xarelto, in patients with acute coronary syndrome. But once again, the attempt failed.
Bayer bucks pharma trend with 'remarkable' growth in new drugs
Bayer's new drugs are bringing home the bacon. The German drugmaker raised its 2015 forecast for 5 key products to €2.5 billion ($3.3 billion)--and confirmed previous promises that those drugs would surpass €5.5 billion by 2020.
Fight for anticoagulant market heats up with antidote deals
What would top Xarelto for Bayer and Johnson & Johnson? Xarelto with an easy antidote.
Clot-fighter Eliquis wins speedy new backing from NICE
The U.K.'s cost-effectiveness watchdogs must really like Eliquis. The new blood thinner from Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) won a thumbs-up for stroke prevention.
Pfizer, Bristol-Myers win landmark European approval for Eliquis
The approval comes after the drug developers had been stiff-armed twice by the FDA, which has now set a March 17, 2013 PDUFA date on the therapy.
Europe adds new uses to Xarelto's marketing arsenal
Rack up another set of new uses for Bayer's Xarelto. The anticoagulant won European approval to treat and prevent pulmonary embolism and to prevent deep vein thrombosis. It's the first warfarin-alternative drug to win these indications, giving it an edge over its rival Pradaxa.
Bayer gambling $4B R&D budget on Xarelto, top blockbuster hopefuls
Bayer Healthcare is on a roll, and it has no intention of easing off the gas now. Emboldened by rising sales of Xarelto, pumped by the prospects of the macular degeneration drug Eylea and optimistic about the newly approved cancer drug Stivarga, Bayer's pharma division has outlined some ambitious plans for its $4 billion annual R&D budget.
J&J's Xarelto nabs new clot-prevention use
Johnson & Johnson ($JNJ) and Bayer's blockbuster candidate Xarelto just won access to a new market--one that could eventually account for about $600 million in sales. It's just the latest in a series of indications added to the clot fighter's label.
Bayer CEO touts Xarelto in Q3 pharma-sales growth
Thank you, Xarelto, Mirena, Cipro and friends. On the strength of these fast-growing products, Bayer's pharma division out-grew its other businesses, with a gain in net sales of 6.1%, to €2.73 billion ($3.545 billion).
